2 4 Zenkuda and KSI-501’s complementary and differentiated product profiles support a broad retinal franchise Phase 3 Study Primary Endpoint 6-Month Durability ZENKUDA RVO (BEACON) DR (GLOW1) DR (GLOW2) wAMD (DAYLIGHT) Not Applicable wAMD (DAYBREAK) Non-Inferiority KSI-501 wAMD (DAYBREAK) Non-Inferiority Not Applicable DME (ALTO) Superiority Across 4 pivotal studies, Zenkuda demonstrated: • Non-inferior efficacy with 6-month predominant durability • Favorable and well-tolerated safety profile • In GLOW1 and GLOW2, Zenkuda reduced the risk of developing a Site Threatening Complication by ≥85% with 100% of patients on 6-month dosing at Year 1 Ongoing DAYBREAK study in wAMD explores potential for immediacy + 4/5/6-month durability • Topline data expected Sept. 2026 Ongoing DAYBREAK study in wAMD explores potential for immediacy + differentiated efficacy • Topline data expected 3Q 2026 ALTO study in DME now enrolling; explores potential for superior efficacy + 4/5/6-month durability Successfully completed Ongoing